Monocentric Observational Study on the Diagnostic and Prognostic Role of 18F-PSMA PET (PET/CT and PET/MR) in Prostate Cancer

Launched by IRCCS SAN RAFFAELE · Dec 4, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how a specific imaging test called 18F-PSMA PET can help in diagnosing and understanding the prognosis of prostate cancer. Researchers want to see how well this test, which uses special images from PET scans, can provide important information about prostate cancer at different stages of the disease. They are particularly interested in new techniques that analyze these images in detail to learn more about the cancer's characteristics.

To be eligible for this study, you must be an adult male with a confirmed diagnosis of prostate cancer who needs staging or restaging, meaning doctors need to assess how advanced the cancer is. Participants will undergo PET scans to help gather valuable information, and the study aims to refine the methods used in this type of imaging. It's important to note that patients with certain medical conditions or allergies that could affect the scan may not be eligible. If you decide to join, you'll be contributing to important research that could improve how prostate cancer is diagnosed and treated in the future.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • adult male patients;
• • patients with histopathological diagnosis of prostate cancer undergoing staging or restaging;
• • patients with clinical indication for PET examination with 18 F-PSMA;
• Exclusion Criteria:
• • medical conditions that do not allow the acquisition of PET images;
• • allergic reactions to iodinated contrast medium or creatinine levels \>2mg/dL.